A Tale of Two Pharmas: Can Obesity Firms Continue Their Outperformance in 2024?

In pharma, you can take a larger slice of the healthcare pie than your peers, but…

Can a Big Pharma Ever Be Worth $1 Trillion?

There are five tech companies valued at over $1 trillion. In healthcare, the closest contender is…

Obesity Drugs Put These Stocks on a Crash Diet—Now They’re Rebounding

There is a bit of cognitive dissonance in healthcare investing right now. After reviewing the highly…

The Trouble With America’s Ultra-Processed Diet

Listen to article (2 minutes) Should your granola bar come with a warning label? Concern is…

Wegovy Maker Novo Nordisk to Spend $6 Billion Boosting Production Capacity

Novo Nordisk, the Danish pharmaceutical giant that makes the blockbuster Wegovy obesity drug, said it will…

Obesity Drug Demand Outstrips Supply

Eli Lilly’s blockbuster diabetes medication Mounjaro is expected to receive Food and Drug Administration approval as…

Never Mind Covid, Investors Want a Pfizer Obesity Pill

Some of this year’s best performers in the healthcare sector are companies expected to profit from…

How weight loss can be a family goal with this new tool to grade obesity

Thirty-five-year-old Amaira (name changed) struggled to breathe in her sleep. At 5 feet 5 inches tall…

Ozempic Boom Is an Opportunity for Health Insurers

You would think a new class of high-price weight loss drugs taken by millions of Americans…

WSJ News Exclusive | The Next Hot Obesity Drug Won’t Be Approved for Years. Online Sellers Hawk It Anyway.

Eli Lilly’s retatrutide will be in clinical trials for the next three years, but knockoff versions…